Stryker Price Target Cut to $300.00/Share From $385.00 by Canaccord Genuity

What happened

Canaccord Genuity cut its price target on Stryker to $300.00 per share from $385.00, and downgraded the stock to Hold from Buy, according to the supplied report.

Confirmed

Global impact / market context

A price target is the analyst's estimate of where a stock could trade in a year. A lower target signals reduced expected upside, while a downgrade to Hold suggests the analyst no longer expects strong enough gains to keep recommending a Buy.

Analyst inference

Stryker makes medical devices, so analyst views on its shares can shape how investors judge the company's future sales and profit. A weaker rating can reduce demand for the stock and raise the cost of raising new money.

Analyst inference

What to watch

1. Canaccord Genuity's new price target is $300.00 per share, down from $385.00. Confirmed
2. Watch whether Stryker's reported sales growth and profit per sale meet the softer outlook implied by the Hold rating. Analyst inference
3. Watch whether other analysts change their own Stryker ratings or targets, which could reinforce or offset this downgrade. Proposed

Evidence

• Original source link unavailable